Which generation is Osimertinib targeted drug?

Osimertinib (Tagrisso) is a targeted drug for non-small cell lung cancer (NSCLC), especially for patients with sensitive EGFR gene mutations. Among many targeted drugs, osimertinib is known as the third-generation EGFR kinase inhibitor, and its emergence has brought new breakthroughs in the field of lung cancer treatment.

Compared with first-generation drugs such as gefitinib, icotinib, and second-generation drug afatinib, osimertinib has significant advantages in efficacy and drug resistance. Although the first two generations of drugs can effectively control the disease, drug resistance often develops after long-term use, affecting the therapeutic effect. Osimertinib can not only be used for first-line treatment, but can also be used as an effective alternative to the first two generations of drugs after resistance. Especially for patients with T790M resistance mutation, osimertinib has shown extremely high efficacy.

In clinical practice, the performance of osimertinib is impressive. Data show that for patients with advanced NSCLC with EGFR mutations, osimertinib can significantly prolong the progression-free survival and improve the quality of life. In addition, osimertinib also has a good control effect on metastatic lesions in the central nervous system, which is a unique advantage compared with other EGFR inhibitors.

However, like all drugs, osimertinib also has certain side effects, such as diarrhea, rash, etc., but usually these side effects are controllable and are better tolerated than traditional treatments such as chemotherapy.

In general, osimertinib, as a third-generation EGFR-targeted drug, plays an increasingly important role in the treatment of non-small cell lung cancer. Its unique efficacy and low side effects make it a shining star in the current field of lung cancer treatment. With the deepening of research and the accumulation of clinical data, we believe that osimertinib will bring hope and hope to more patients.